China's Largest Pharma Promoter CMS Outpaced Market With Unique Specialty Pharma Focus
This article was originally published in PharmAsia News
SHANGHAI - China Medical System Holdings, the largest third-party promotion service company in China, differs from its competitors by targeting small- and mid-size specialty pharma as clients, giving the company more secure contracts, higher profile products and bigger margins
You may also be interested in...
China Medical System has agreed to pay a total of $500m for selected rights to two mature AstraZeneca cardiovascular products, with the divestments set to provide new growth prospects for the Chinese firm while helping the UK-based multinational focus on innovative products in its second-largest global market.
PharmAsia News takes a closer look at how China’s largest third-party promotion company and second-largest domestic pharma have responded to price cuts and hospital reform.
SHANGHAI - China's largest vaccine distributor China NT Pharma Group announced Aug. 17 it will not renew its master distribution contract with its largest customer GlaxoSmithKline PLC, in part, it appears, due to burdens created by the new China Pharmacopeia that was issued at the end of 2010